Company Research Report: Angitia Biopharmaceuticals
Company Overview
Name
Angitia Biopharmaceuticals
Mission
To discover, develop, and commercialize breakthrough therapeutics that address large unmet medical needs of patients with serious musculoskeletal diseases.
Founded
2018
Founders
- Hua Zhu (David) Ke, MD
Key People
- Hua Zhu (David) Ke, MD: Founder, Chairman, CEO
- Willard Dere, MD, FACP: Chief Medical Officer, Chief Advisor to CEO
- Muyu (Luna) Li, MBA: Co-founder, Chief Operating Officer
- Mike Arenberg, JD, MBA: Chief Financial Officer
- Lei Zheng, PhD: Chief Technology Officer
- Xiaofeng Liu, PhD: Head of Discovery Research
- Ann Zovein, MD, MBA: Head of Translational Science
- Ricardo Dent, MD: Head of Global Clinical Development
- Tom Storey, MBS, MBA: Head of Business Development
Headquarters
Woodland Hills, California, USA
Number of Employees
No information is available
Revenue
No information is available
Specialization
Angitia Biopharmaceuticals is known for its focus on discovering and developing breakthrough therapeutics for serious musculoskeletal diseases.
Products
Product Pipeline
1. AGA111
- Indication: Spinal Fusion
- Development Stage: Phase III
- Key Features: A drug candidate showing excellent safety and preliminary efficacy in lumbar interbody fusion.
2. AGA2118
- Indication: Osteoporosis
- Development Stage: Phase I
- Key Features: Demonstrates an excellent safety and tolerability profile, as well as preliminary efficacy in increasing bone mineral density (BMD) after single and multiple dose administrations.
3. AGA2115
- Indication: Osteogenesis Imperfecta
- Development Stage: Phase I
- Key Features: Evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics for treatment of osteogenesis imperfecta.
Recent Developments
May 16, 2024
- Event: Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2118
- Details: Positive results from the Phase I study demonstrating excellent safety and tolerability profile along with preliminary efficacy in increasing bone mineral density (BMD).
April 9, 2024
- Event: Appointment of Michael H. Arenberg as Chief Financial Officer
- Details: Michael H. Arenberg, J.D., M.B.A., appointed as CFO, effective April 8th, 2024.
February 28, 2024
- Event: Completion of US$40M Second Close of Series B Extension Financing
- Details: Led by YueKai Health, this additional funding brings the total Series B Extension financing to US$86M.
December 8, 2023
- Event: First Subject Dosed in Phase III Registrational Trial of AGA111
- Details: Significant milestone in the development of AGA111, with the first subject successfully dosed in a Phase III trial.
October 19, 2023
- Event: Completion of $46M Series B Extension Financing
- Details: Funding led by Morningside Group, syndicated by multiple investment firms, totaling US$170M for the financing round.
October 17, 2023
- Event: First Subject Dosed in Phase I Trial of AGA2115
- Details: Initiation of a First-in-Human trial for AGA2115 to treat osteogenesis imperfecta.
October 16, 2023
- Event: NMPA Grants Phase III IND Approval for AGA111
- Details: Approval for the Phase III study of AGA111 following encouraging Phase I/II trial results.
October 13, 2023
- Event: David Ke Appointed as Honorary Professor by Hong Kong Baptist University
- Details: Recognition of Dr. Ke’s contribution to drug discovery and education, with a focus on innovative therapies for bone diseases.
August 19, 2023
- Event: FDA Clearance of IND Application for AGA2115
- Details: Approval for the Phase I trial to evaluate AGA2115, an investigational therapy for osteogenesis imperfecta.
Conclusion
Angitia Biopharmaceuticals is dedicated to the development of innovative therapies addressing serious musculoskeletal diseases. The company is actively advancing its product pipeline with several key therapeutics in various stages of clinical trials, supported by significant financial backing and a robust leadership team.
